The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 300 members and is the leading global advocacy organization in this field. www.alliancerm.org
Sponsor the Program
Interested in gaining exposure to hundreds of leading decision makers in the field? Contact Laura Parsons at firstname.lastname@example.org for more information on sponsorship and raise your profile at this year’s conference.
In Collaboration With
EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our seven landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe, BIO-Europe Spring, BioPharm America, Biotech Showcase, ChinaBio Partnering Forum, Cell & Gene Exchange, and BioEquity Europe) annually attract more than 12,000 senior life science executives who engage in over 43,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry. www.ebdgroup.com
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life. The company is organized into two market-focused segments: Pharma and Biotech and Specialty Ingredients. The core competencies that span these segments are advanced manufacturing and quality-control systems, superior regulatory expertise, in-depth market knowledge and extensive technical customer-support and research and development capabilities. www.lonza.com
Cryoport is the premier provider of temperature controlled logistics solutions to the life sciences industry through our purpose-built proprietary packaging, information technology and specialized logistics expertise. We provide leading-edge temperature controlled logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide including points-of-care, CROs, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. Cryoport’s unparalleled information technology centers around our proprietary Cryoportal® Logistics Management Platform, which facilitates management of the entire shipment process. Our state-of-the-art technology also includes our innovative Smartpak II™ Condition Monitoring System, which provides visibility of the location and the key aspects of critical shipments. The Smartpak II™ works in conjunction with our Cryoportal® to provide real-time information reporting about shipments, integrated condition monitoring, logistics and shipper qualification performance in a single data steam. Cryoport also has a dedicated 24/7/365 customer service team to proactively monitor each shipment, allowing for invention when necessary. www.cryoport.com
Medpace is a global full-service clinical research 0rganization (CRO) providing comprehensive development services for drug, biologic and device programs with a specialized focus on advanced therapies including cell and gene therapies. Medpace has strong experience supporting development programs for regenerative medicine products across a number of therapeutic areas including cardiovascular, neuroscience, musculoskeletal and diabetes. With extensive medical expertise, a renowned regulatory affairs department, across six continents, Medpace conducts studies and navigates regulatory requirements worldwide. From feasibility, research site compatibility, safety and logistics, Medpace brings efficiencies and operational excellence to regenerative medicine development programs. In addition, Medpace offers integrated imaging and lab capabilities through its family of companies to provide cohesive, streamlined and standardized trial management. Learn more about Medpace’s focus on cellular, tissue and gene therapy medicines at www.medpace.com.
MolMed S.p.A. is an Italian biotechnology cell and gene company, focused on research, development, manufacturing and clinical validation of innovative therapies in oncology and rare diseases. MolMed built an original dual business model, based on research and development of proprietary products, and third party GMP services. MolMed is currently the developer and manufacturer for worldwide leaders in the field of gene therapy for rare diseases and allogenic CAR-T therapies supporting their clinical trials and commercial supply. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange and has been managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department and has an operating unit at OpenZone in Bresso. www.molmed.com
Invitrx Therapeutics is a leader in birth tissue research and pioneer in the field of regenerative stem cell therapies. Invitrx was established through wound healing funding in 2003 by CEO, Habib Torfi. In this time, Invitx has grown as an innovator of stem cell products and is developing therapies from amniotic stem cells, cord blood stem cells, placental stem cells and Wharton’s jelly stem cells. Our pursuit for innovation has led to a new $7 million facility being opened in Lake Forest, CA in July of 2018. This facility includes three clean rooms, a flow cytometry core and ultracentrifuges. These resources will push for exosomal research. Publishing in renowned journals has illuminated the age of exosomes and these minuscule molecules have the potential to attenuate diseases and possibly improve the quality of life for millions of people. Invitrx hopes to alleviate the symptoms of osteoarthritis and eliminate opioid dependency. www.invitrx.com
Precision BioSciences is a privately held biotechnology company dedicated to improving lives through its next generation gene editing technology, ARCUS. Precision’s approach is based on a proprietary synthetic enzyme, the ARC endonuclease, which features coordinated target site binding and DNA cutting to ensure precise editing outcomes. Uniquely small and monomeric, ARC nucleases are readily delivered to target sites throughout the genome and across cell types and tissues. The value of the ARCUS editing platform is enhanced by Precision’s extensive patent portfolio, established freedom to operate and deep collaborative relationships, positioning Precision to create products that solve significant problems in oncology, genetic disease, agriculture and beyond. Our team includes pioneers in genome engineering and a staff of experienced, committed Precisioneers. Working together in the vibrant innovation center of Durham, NC, we are excited to lead the next wave of medical and scientific possibilities through continuous gene editing innovation. www.precisionbiosciences.com
The FreeMind Group is the premier international consulting firm specializing in assisting life science organizations to secure non-dilutive funding from U.S. federal agencies and private foundations. Founded in 1999, The FreeMind Group is the largest consulting group of its kind and works with a variety of life sciences organizations, from small startups to large pharmaceutical companies. FreeMind’s proven long-term strategic approach has garnered its clients over $1.5 billion to date in non-dilutive funding. The FreeMind team combines their extraordinary scientific understanding, innovative business and financial expertise and creative writing and presentation skills to cater to the specific and unique needs of academic and research institutions as well as the life science industry. www.freemindconsultants.com